Orphan Drug Coverage In Exchange Plans Explored In Study
This article was originally published in The Pink Sheet Daily
Researchers from Avalere and the National Organization for Rare Disorders find orphan drugs that are the only products in their class, such as Amgen’s Sensipar, have “relatively robust” coverage in a selection of popular health plans sold through exchanges in 15 states.
You may also be interested in...
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.